The ReCor renal denervation system for treating refractory hypertension is safe and effective but further study is needed in vulnerable subpopulations, an FDA advisory panel concludes.
A federal advisory panel offered a bevy of suggestions about how the FDA might proceed with potential future clearances for the broad use of tools intended to analyze skin lesions for cancer risk.